Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by a low platelet count. It is treated with a variety of hematological drugs, including corticosteroids, immunosuppressants, and anticoagulants. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the body's production of antibodies. Anticoagulants are used to prevent the formation of blood clots. These drugs are used in combination to reduce the risk of bleeding and improve platelet counts. The market for TTP drugs is highly competitive, with a number of companies offering a range of products. Some of the major players in the market include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. Other companies include AbbVie, AstraZeneca, and Sanofi. These companies offer a range of products, including generic and branded drugs, to meet the needs of patients with TTP. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
